Ipilimumab Dilution for Intravenous Infusion
Ipilimumab (YERVOY) is supplied as a 5 mg/mL solution and should be diluted in either 0.9% sodium chloride injection or 5% dextrose injection to prepare the final infusion solution for intravenous administration 1.
Preparation Steps
Vial Specifications
- Available as 50 mg/10 mL or 200 mg/40 mL single-dose vials
- Concentration: 5 mg/mL
- Discard any unused portion after withdrawal 1
Dilution Procedure
Calculate the required dose based on patient body weight:
- Standard dosing ranges from 1 mg/kg to 3 mg/kg depending on the indication and combination regimen 2, 1
- For metastatic melanoma monotherapy: 3 mg/kg
- For combination with nivolumab: typically 1 mg/kg or 3 mg/kg depending on protocol
Dilution specifications:
- Use either 0.9% sodium chloride injection (most common) or 5% dextrose injection as diluent 1, 3
- The FDA label specifies these are the approved diluents for ipilimumab
- Saline is the most frequently recommended diluent for therapeutic antibodies in general practice 3
Critical Handling Points
Visual inspection: The solution should be clear to slightly opalescent, colorless to pale-yellow, and may contain small amounts of visible translucent-to-white amorphous particulates 1. This is normal and does not require filtration unless institutional protocols specify otherwise.
Infusion rate:
- Standard infusion time is 90 minutes per FDA labeling 1, 4, 5
- Research evidence suggests 30-minute infusions may be safe with acceptable infusion-related reaction rates (5.8% vs 2.2% for 90-minute infusions, though not statistically significant) 6
- However, adhere to the FDA-approved 90-minute infusion time unless your institution has specific protocols for shortened infusion
Important Caveats
Stability considerations: Weight-based dosing creates varying final drug and excipient concentrations that can affect stability 7. Prepare solutions close to administration time and avoid prolonged storage after dilution.
Infusion-related reactions: Monitor closely during infusion for chills, rash, flushing, wheezing, dizziness, fever, or back/neck pain 1. Most reactions occur at dose 2 if they occur 6.
Polysorbate 80 hypersensitivity: Ipilimumab contains polysorbate 80 as an excipient 1. Patients with confirmed PS80 allergy require specialized desensitization protocols 8.